BioNTech reports overall survival benefit in late-stage lung cancer trial
BioNTech said its Phase 3 PRESERVE-003 trial showed a clinically meaningful overall survival benefit in a certain form of lung cancer compared with standard treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.